ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,930.40
0.22%
US Tech 100
20,124.80
-0.01%
Dow Jones
43,771.28
0.84%
Brent Oil
73.395
0.76%
Bitcoin
97,114.24
2.91%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Lyell Immunopharma Inc (LYEL) Quote

Lyell Immunopharma Inc

Lyell Immunopharma Inc (LYEL)

NASDAQ
0.9627
-0.0673
( -6.53% )
Updated: 11:45:25
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.9627
Bid
0.9613
Ask
0.9628
Volume
324,610
0.95 Day's Range 1.04
0.85 52 Week Range 3.2556
Market Cap
268.806M
Previous Close
1.03
Open
1.01
Last Trade
100
@
0.9627
Last Trade Time
11:45:25
Financial Volume
$ 319,038
VWAP
0.982835
Average Volume (3m)
1,236,927
Shares Outstanding
279,220,614
Dividend Yield
-
PE Ratio
-1.13
Earnings Per Share (EPS)
-0.84
Revenue
2.92M
Net Profit
-234.63M

About Lyell Immunopharma Inc

Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors). Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
lyell.com
Headquarters
Dover, Delaware, USA
Founded
-
Lyell Immunopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LYEL. The last closing price for Lyell Immunopharma was $1.03. Over the last year, Lyell Immunopharma shares have traded in a share price range of $ 0.85 to $ 3.2556.

Lyell Immunopharma currently has 279,220,614 shares outstanding. The market capitalization of Lyell Immunopharma is $287.60 million. Lyell Immunopharma has a price to earnings ratio (PE ratio) of -1.13.

Ask ADVFN Intelligence (AI)

LYEL Latest News

More News

Form 8-K - Current report

November 07 2024
Edgar (US Regulatory)

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with...

November 07 2024
GlobeNewswire Inc.

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for...

November 05 2024
GlobeNewswire Inc.

Form 8-K - Current report

October 31 2024
Edgar (US Regulatory)

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in...

October 31 2024
GlobeNewswire Inc.

Form 8-K - Current report

October 24 2024
Edgar (US Regulatory)

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s multi-center Phase 1-2 clinical trial of IMPT-314 in...

October 24 2024
GlobeNewswire Inc.

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

October 04 2024
GlobeNewswire Inc.

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

September 24 2024
GlobeNewswire Inc.

Lyell Immunopharma Announces Participation in September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell...

August 28 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1473-13.27027027031.111.160.863817728121.06584369CS
4-0.1873-16.28695652171.151.49990.8523954121.04144149CS
12-0.5173-34.95270270271.481.60.8512369271.14141388CS
26-1.6573-63.25572519082.622.850.8510488021.41864472CS
52-0.9273-49.06349206351.893.25560.8510582941.78615211CS
156-9.7473-91.011204481810.7110.960.8510258253.54730182CS
260-17.7873-94.865618.7519.840.859527524.21786104CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 2.07
(111.22%)
110.56M
CRNCCerence Inc
$ 4.675
(65.78%)
35.57M
QUBTQuantum Computing Inc
$ 5.095
(38.45%)
92.52M
SPAISafe Pro Group Inc
$ 4.4123
(37.88%)
37.01M
IBGInnovation Beverage Group Limited
$ 1.06
(33.97%)
9.6M
GLXGGalaxy Payroll Group Ltd
$ 1.51
(-61.38%)
1.01M
PYXSPyxis Oncology Inc
$ 2.10
(-45.03%)
10.14M
KURAKura Oncology Inc
$ 9.92
(-37.65%)
8.27M
BLRXBioLineRx Ltd
$ 0.355
(-34.89%)
6.39M
TMTCTMT Acquisition Corporation
$ 4.52
(-29.81%)
18.84k
CDTConduit Pharmaceuticals Inc
$ 0.112951
(22.37%)
499.7M
NVDANVIDIA Corporation
$ 144.855
(-0.71%)
212.11M
AKTSAkoustis Technologies Inc
$ 0.0985
(13.09%)
185.68M
ELABElevai Labs Inc
$ 0.0201
(-6.07%)
175.91M
WORXSCWorx Corporation
$ 2.07
(111.22%)
110.56M

LYEL Discussion

View Posts
glenn1919 glenn1919 2 weeks ago
lyel..............................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 weeks ago
LYEL................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 4 weeks ago
As a reminder, the ORR was ~12.5% for LYL797. BMY's JCAR024 had an ORR of 5-6%, but was discontinued, while a Fred Hutch construct showed no responses.
👍️0
jondoeuk jondoeuk 4 weeks ago
An update https://www.globenewswire.com/news-release/2024/10/24/2969054/0/en/Lyell-Immunopharma-to-Acquire-ImmPACT-Bio-and-Prioritizes-its-Pipeline-to-Focus-on-Next-Generation-CAR-T-cell-Therapies.html

The webcast https://lyell-company-update-2024.open-exchange.net/registration

Slides https://ir.lyell.com/static-files/40d6bd34-9ad0-49dd-b816-4bda3bd53eb0
👍️0
glenn1919 glenn1919 4 weeks ago
LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 2 months ago
Preclinical data (Stim-R tech) https://www.nature.com/articles/s41598-024-72392-1
👍️0
glenn1919 glenn1919 3 months ago
LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 5 months ago
(OT) Dr Restifo is Co-founder and Chief Scientist at Marble Therapeutics. From this: ''At Marble Therapeutics, he is working to figure out how to rewind the epigenetic clock on these cells, using any means possible. The company started out with a focus on skin rejuvenation, adds CEO Denitsa Milanova, but expanded to also work on adoptive cell therapy to prove their platform works.'' https://web.archive.org/web/20231218233715/https://www.nature.com/articles/d41573-023-00206-6

They have a license for TIL plus a neoantigen vaccine https://www.federalregister.gov/documents/2024/02/07/2024-02491/prospective-grant-of-an-exclusive-patent-license-vaccine-augmented-adoptive-cell-therapy-for-the

Preclinical data on the vaccine https://jitc.bmj.com/content/11/Suppl_1/A418
🎯 1 👍️ 1
glenn1919 glenn1919 7 months ago
LYEL.....................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 7 months ago
LYEL active in the Gaucho session

👍️0
jondoeuk jondoeuk 8 months ago
Tempting but I will remain on the sidelines.
👍️0
Monksdream Monksdream 8 months ago
LYEL under $3
👍️0
glenn1919 glenn1919 8 months ago
LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 1 year ago
They could be working on this https://ash.confex.com/ash/2023/webprogram/Paper182417.html
👍️0
jondoeuk jondoeuk 1 year ago
Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750444/0/en/Lyell-Immunopharma-Announces-the-Acceptance-of-Six-Abstracts-for-Presentation-at-2023-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html
👍️0
Monksdream Monksdream 1 year ago
LYEL new 52 week low
👍️0
jondoeuk jondoeuk 2 years ago
LYL119 https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=13739
👍️0
jondoeuk jondoeuk 2 years ago
Preclinical data from another group (LYL119 will be NR4A3-deficient) https://www.biorxiv.org/content/10.1101/2023.04.21.537841v1.full
👍️0
glenn1919 glenn1919 2 years ago
LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783
👍️0
jondoeuk jondoeuk 2 years ago
The FDA has cleared an IND for LYL845. The PhI trial will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into NSCLC and CRC. Initial data presentation is expected in 2024.
👍️0
jondoeuk jondoeuk 2 years ago
SITC titles

NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo

Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity

Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology
👍️0
NY1972 NY1972 2 years ago
recent technical advances using culture conditions with IL-7/IL-15 and
the addition of IL-21 may enhance the enrichment for TSCM cells
in the final CART product (74–76), which can be further increased
with the addition of drugs blocking T-cell differentiation, such as
glycogen synthase-3 inhibitors (77). Nevertheless, robust clinical grade protocols for generating TSCM-enriched CART products
have not been developed so far. Recently, a few CART19 clinical
trials for DLBCL have been conducted in which CART products
were manufactured from CD62L+ isolated T cells to generate
cellular products enriched for TCM cells (21, 78); however, due to
prolonged culture conditions, enrichment for TSCM and TCM
subsets in the infused product could not be demonstrated

https://www.frontiersin.org/articles/10.3389/fimmu.2022.904497/full
👍️0
jondoeuk jondoeuk 2 years ago
The AEs from the LD chemo*. I expect more data (dose expansion is ongoing) from them at ASH. As for NVS, a pivotal trial is planned and DL2 (12.5M) is the recommended dose.

* Some very early clinical data testing an anti-GD2 CAR-T with constitutive signaling from an engineered IL-7 receptor
👍️0
NY1972 NY1972 2 years ago
Thanks for the link.
Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%

Compared to T-Charge
http://www.koreabiomed.com/news/articleView.html?idxno=12767

👍️0
jondoeuk jondoeuk 2 years ago
For Epi-R, they use media with high concentrations of potassium (as well as multiple cytokines). As for that, T-Charge or BE, I think a product with mostly ''stem-like'' cells and additional edits will be needed. But it doesn't have to be the latter, as shRNA can be used. Here are some clinical data on an anti-CD19 CAR-T with knock-down of both PD-1 and TIGIT https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7522
👍️0
NY1972 NY1972 2 years ago
Which will perform better ? BE with 7,8 edits on many genes, Epi secret sauce
or T-Charge which seems to add a CAR only to starting material in order to retain CD4/CD8 ratio.
YTB323 CAR-T cell products generated via this novel expansionless manufacturing process retained the immunophenotype of the input leukapheresis materia
👍️0
jondoeuk jondoeuk 2 years ago
That depends. Typically, the more the cells expand during manufacturing, the more they differentiate. In the case of ALLO, it seems most are effector memory (manufacturing time is ~19 days and there are a number of steps involved). LYEL refer to this as the expansion/quality paradox. With Epi-R, they have shown they can expand TCR-T cells up to 18 billion by day ten. In addition, these cells are over 94% viable and maintain their ''stem-like'' qualities.
👍️0
NY1972 NY1972 2 years ago
Do you need Epigenetic Reprogramming if pts can be treated with healthy, young donor T cells?
👍️0
jondoeuk jondoeuk 2 years ago
ISSCR poster https://ir.lyell.com/static-files/971404cb-28eb-46fc-839f-b20735899373
👍️0
jondoeuk jondoeuk 3 years ago
Posters https://ir.lyell.com/static-files/d3a3d05c-1b39-4092-bf82-a486933bc268

https://ir.lyell.com/static-files/6014be8d-4e9d-499b-a496-513d2962f3e4
👍️0
jondoeuk jondoeuk 3 years ago
1115: Epigenetic Reprogramming (Epi-R™) Yields T-Cell Receptor Products with Improved Stemness, Metabolic Fitness, and Functional Activity in the Presence of Persistent Antigen Exposure https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2014

661: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1597
👍️0
jondoeuk jondoeuk 3 years ago
GSK has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses Epi-R.
👍️0
jondoeuk jondoeuk 3 years ago
AACR poster https://ir.lyell.com/static-files/ad2cd8dc-b41b-4536-a854-c4d1246422e6
👍️0
jondoeuk jondoeuk 3 years ago
The PhI (n=54) of LYL797 has now been listed. The dose-escalation phase (TNBC only) will investigate four dose levels to determine the recommended RP2D. The dose expansion will enroll both TNBC and NSCLC.
👍️0
jondoeuk jondoeuk 3 years ago
A new review https://www.sciencedirect.com/science/article/pii/S0952791521001278
👍️0
jondoeuk jondoeuk 3 years ago
Morgan Stanley webcast https://morganstanley.webcasts.com/viewer/event.jsp?ei=1488969&tp_key=3cedc4a917
👍️0
jondoeuk jondoeuk 3 years ago
New deck https://ir.lyell.com/static-files/96379999-4d8e-466b-a5d5-44f5f6f88583
👍️0

Your Recent History

NASDAQ
LYEL
Lyell Immunopharma
NASDAQ
HOLO
MicroCloud Hologram
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved